Asthma

Atrial Fibrillation

Autoimmune Diseases

Biologics

Biosimilars

Blood Cancer

Breast Cancer

COVID-19

Cardiovascular Diseases

Depression

Dermatology

Diabetes

Digital Health

Drug Coverage

Duchenne Muscular Dystrophy

Eyecare

Friedreich Ataxia

Gene Therapy

Graft Versus Host Disease

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Infectious Disease

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Nephrology

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

PTSD

Pain

Pediatrics

Plaque Psoriasis

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Pulmonary Arterial Hypertension

Reproductive Health

Respiratory Conditions

Safety & Recalls

Schizophrenia

Skin Cancer

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type I Diabetes

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

Women's Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Formulary Watch Spotlights

Supplements And Featured Publications

Events

Webinars

CME/CE

Resources

PBMI Innovators

Emerging Leaders

Interactive Tools

PBM Directory

Subscribe

Videos

The next step for the Rise For Health study researchers is to study the health benefits of frequent standing in older men and women. 

Postmenopausal Women Aren’t The Only Ones Who Could Benefit From Frequent Standing  

Articles

Sexual and gender minority individuals still face insurance denials and cost-sharing barriers when accessing pre-exposure prophylaxis (PrEP), despite having a Grade A recommendation from the United States Preventive Services Task Force (USPSTF). 

A Conversation With Alexa D’Angelo, Ph.D., M.P.H., Recent Doctoral Graduate from the CUNY School of Public Health and Health Policy

The biosimilar will be available to any licensed specialty pharmacy in the United States at a 95% discount from Stelara, starting January 1, 2026. 

MedImpact To Offer Unbranded Ustekinumab-aekn Biosimilar 

Large language models (LLMs) were more likely to suggest inferior treatment options when reviewing hypothetical cases when patients' Black identity was listed or implied.

 Schizophrenia Diagnoses Have Highest Likelihood of AI Racial Bias, Study Shows 

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive - Payer and Population Health Insights

Facebook

LinkedIn

Resource Centers

Eye Care

Spotlight

ASRS 2025

IAS 2025

AMCP Annual

K-Cast: Optimizing Narcolepsy Care

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

View

Insights into Digital Therapeutics Space and Associated Evidence Thresholds

Video Series

Evidence Thresholds for Prescription vs Non-Prescription Digital Therapeutics

Diana Brixner, PhD, FAMCP, of the University of Utah opens a discussion surrounding digital therapeutics.

Dr Brixner expands on evidence thresholds in the digital therapeutic space.

Industry Collaboration in Shaping Digital Therapeutics Standards 

Payer Challenges in Evaluating Digital Therapeutics 

Diana Brixner, PhD, FAMCP, examines the payer perspective on including Prescription Digital Therapeutics in formularies, utilizing real-world evidence as a key metric to assess the impact, cost-effectiveness, and patient benefit of these innovative digital treatments.

Cost-Effectiveness Metrics Payers Seek for Digital Therapeutics

A medical expert explores the development of prescription digital therapeutic models, including insurance investment in prescription digital therapeutics and telemedicine, as well as employer-sponsored benefits for non-prescription digital therapeutics and wellness initiatives aimed at improving overall health outcomes.

Developing Reimbursement Models for Digital Therapeutics

Adoption Lessons For Payers 

Gaps in Evidence Generation for Digital Therapeutics 

Overcoming Implementation Barriers for Digital Therapeutics Adoption 

Evidence Thresholds for Prescription vs Non-Prescription Digital Therapeutics

EP: 1.Insights into Digital Therapeutics Space and Associated Evidence Thresholds

EP: 2.Evidence Thresholds for Prescription vs Non-Prescription Digital Therapeutics

EP: 3.Industry Collaboration in Shaping Digital Therapeutics Standards

EP: 4.Payer Challenges in Evaluating Digital Therapeutics

EP: 5.Cost-Effectiveness Metrics Payers Seek for Digital Therapeutics

EP: 6.Developing Reimbursement Models for Digital Therapeutics

EP: 7.Adoption Lessons For Payers

EP: 8.Gaps in Evidence Generation for Digital Therapeutics

EP: 9.Overcoming Implementation Barriers for Digital Therapeutics Adoption

Newsletter